Clinical Trial

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2026-03-22
Trial Details
NCT Number NCT07366866
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Autoimmune Disease
Enrollment 48 participants
Start Date 2026-03-16
Primary Completion 2027-02-07 (estimated)
Study Completion 2027-03-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-25